Medication info
Shubastin Tablet 20 Milligrams (Rosuvastatin Calcium)

Shubastin Tablet 20 Milligrams (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Vivozon Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201504203 · Approved 2015.06.29 · Insurance code 658202860

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; the dose may be adjusted as a maintenance dose if a greater reduction in LDL cholesterol is needed. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or more according to the LDL cholesterol level, treatment goal, and patient response, and may be increased up to a maximum of 20 milligrams daily. 3. Older patients: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: Systemic exposure to rosuvastatin did not increase in patients with a Child-Pugh score of 7 or less, but increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Children's dosage
Ages 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) Under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Vivozon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, prevention of cardiovascular disease

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • atherosclerosis
  • homozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol level
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is primarily used as an adjunct to diet for patients with primary hypercholesterolemia and mixed dyslipidemia. It is also administered in combination with dietary changes or lipid-lowering therapy for patients with homozygous familial hypercholesterolemia. It effectively lowers total cholesterol and LDL cholesterol levels, delaying the progression of atherosclerosis. In pediatric patients, it helps reduce cholesterol levels when LDL cholesterol levels are high despite strict dietary restrictions. Additionally, it is used as an adjunct to diet in patients with primary dysbetalipoproteinemia. Furthermore, in high-risk cardiovascular disease patients with elevated high-sensitivity C-reactive protein levels, it is used to reduce the risk associated with stroke, myocardial infarction, and arterial revascularization. Therefore, this medication is effectively used for various types of dyslipidemia and the reduction of cardiovascular risk.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; the dose may be adjusted as a maintenance dose if a greater reduction in LDL cholesterol is needed. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or more according to the LDL cholesterol level, treatment goal, and patient response, and may be increased up to a maximum of 20 milligrams daily. 3. Older patients: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: Systemic exposure to rosuvastatin did not increase in patients with a Child-Pugh score of 7 or less, but increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Children's dosage

Ages 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) Under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be administered to certain patients. For example, it should not be used in patients with an allergy to any component of this medication, those with severe liver impairment, patients with muscle disorders, patients taking certain immunosuppressants, patients with severe renal impairment, pregnant or breastfeeding women, and women of childbearing age who are not using adequate contraception. Additionally, high-dose administration is prohibited in patients at high risk for muscle disorders. Risk factors include moderate renal impairment, hypothyroidism, family history of muscle disorders, and alcohol abuse. This medication contains lactose, therefore it should not be taken by patients with lactose intolerance. Caution should be exercised in patients who consume excessive alcohol or have a history of liver disease, and regular liver function tests are recommended. If symptoms such as myalgia, muscle weakness, or cramps occur, the physician should be informed immediately, and if necessary, blood tests should be conducted to check for muscle damage. If severe muscle damage is suspected, the medication should be discontinued. In cases of acute severe illness or after surgery, or if there are severe metabolic disorders, the administration of this medication should be halted. Rarely, this medication can cause severe skin reactions or liver damage, so if any rashes, jaundice, or severe fatigue occur, treatment should be stopped immediately and a physician should be consulted. This medication may interact with various other drugs, so if other medications are being taken, it is essential to inform the physician or pharmacist. In particular, the risk of muscle damage may increase when used concurrently with certain antiviral drugs, immunosuppressants, antibiotics, and lipid-lowering agents. Women who are pregnant or planning to become pregnant should not take this medication, and if pregnancy occurs while taking it, the medication should be immediately discontinued. Nursing women should also refrain from using this medication. In case of overdose, there are no specific antidotes, so appropriate treatment and monitoring will be necessary based on the symptoms. Care should be taken when driving or operating machinery as dizziness may occur. This medication may exhibit higher plasma concentrations in Asian individuals, hence dosage adjustments may be necessary. It is important to regularly check liver function and muscle-related tests for abnormalities while taking this medication.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, shortness of breath, diarrhea, ocular muscle weakness, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, ALT elevation, chest pain, muscle cramps, fatigue, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, gout, erectile dysfunction, acute renal failure, oliguria, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is advisable to maintain the storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.